Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
An update from Mesoblast Limited ( (AU:MSB) ) is now available.
Mesoblast Limited has applied for quotation on the ASX of 7,335,000 new fully paid ordinary shares, issued on 19 December 2025 under an employee incentive scheme. The move expands the company’s quoted share capital and reflects ongoing use of equity-based incentives to attract and retain staff, a practice that can influence capital structure and potentially dilute existing shareholders while aligning employees’ interests with long-term company performance.
The most recent analyst rating on (AU:MSB) stock is a Buy with a A$4.00 price target. To see the full list of analyst forecasts on Mesoblast Limited stock, see the AU:MSB Stock Forecast page.
More about Mesoblast Limited
Mesoblast Limited is an Australia-listed biotechnology company trading under the ASX code MSB. The company focuses on developing and commercialising cellular medicines, with operations and investor base centred on the Australian securities market.
Average Trading Volume: 4,197,680
Technical Sentiment Signal: Buy
Current Market Cap: A$3.94B
See more data about MSB stock on TipRanks’ Stock Analysis page.